Vecura Manufacture
Vecura – An Infrastructure for Development and Manufacturing of ATMPs.
The project involves development of three different GMP-compliant processes used in manufacturing of ATMPs.
Period: 09/2021 – 08/2023
Lead: Pontus Blomberg, Karolinska University Hospital
Involved partners: Vecura/Karolinska University Hospital, Karolinska Institutet, Cytiva, NEOGAP, XNK Therapeutics
- Subproject – Expansion of GMP Compliant Tumor Infiltrating Lymphocytes (TILs) in Xuri bioreactor (continuation)
- Subproject – Expansion of GMP-compliant adaptive T-cells in bioreactor
- This project aims towards the establishment of an automated closed system for manufacturing of adoptive T- cells for cancer treatment.
- Time period: 09/2021 – 08/2023.
- Lead: Pontus Blomberg, Karolinska University Hospital.
- Involved partners: NEOGAP AB, VivaBioCell
- Subproject – Cell processing of NK-cells using Sepax cell processing instrument
- The project will explore the feasibility of the applications of the Sepax C-Pro in the CellProtect work-flow including procurement of cells, thawing and resuspension and harvest from bioreactor.
- Time period: 09/2021 – 08/2023.
- Lead: Pontus Blomberg, Karolinska University Hospital.
- Involved partners: XNK AB, Cytiva AB
Publications
”Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination.” see project page
”Human serum albumin as a clinically accepted cell carrier solution for skin regenerative application.” see project page
”Karolinska Institutet Human Embryonic Stem Cell Bank.” see project page
”Gene therapy – from idea to reality” (Swedish)
”A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.”